What is EN ISO 10993-17:2021?

The international standard EN ISO 10993-17:2021, released by the International Organization for Standardization (ISO), specifically focuses on biological evaluation of medical devices. It provides guidance on conducting tests to determine the potential for medical devices to cause irritation and skin sensitization.

The Importance of EN ISO 10993-17:2021

In the field of medical devices, it is crucial to ensure that they are safe for patients to use. EN ISO 10993-17:2021 plays a significant role in this process by providing a standardized way of evaluating the biological risks associated with medical devices.

By following the guidelines outlined in EN ISO 10993-17:2021, manufacturers can assess the potential for their products to cause skin irritation or sensitization before they are introduced to the market. This helps to prevent adverse reactions and ensures patient safety.

The Testing Process

The standard outlines a systematic approach to conducting tests for skin irritation and sensitization. It considers both in vitro and in vivo testing methods, allowing manufacturers to choose the most appropriate approach based on the characteristics of the medical device.

The testing process involves exposing the device to specific cells, tissue samples, or animal subjects to evaluate any potential adverse effects. These tests aim to detect skin irritants and sensitizers, providing valuable information for risk assessment.

Compliance and Benefits

Adhering to EN ISO 10993-17:2021 is not only beneficial for ensuring patient safety, but also essential for compliance with regulatory requirements. Medical device manufacturers need to demonstrate compliance with this standard to obtain the necessary certifications and approvals for their products.

Furthermore, compliance with EN ISO 10993-17:2021 enhances the reputation of manufacturers and inspires confidence among healthcare professionals and patients. It demonstrates their commitment to producing safe and reliable medical devices.